Medication info
Hanubiem Tablet 50/500 mg

Hanubiem Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 201503215 · Approved 2015.05.27 · Insurance code 647805510

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood glucose control in patients with type 2 diabetes. It helps manage blood glucose levels more effectively when taken together with dietary regulation and exercise therapy. The two active ingredients, sitagliptin and metformin, work together to enhance blood glucose control. Therefore, this medication is beneficial for individuals who need blood glucose management and exerts positive effects on overall diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).

Precautions

This medication contains sitagliptin and metformin and is used for the treatment of diabetes. First, during the use of this medication, serious allergic reactions may occur, so if symptoms such as skin rash, hives, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a healthcare professional. Additionally, this medication may cause inflammation of the pancreas (pancreatitis). If symptoms such as abdominal pain, nausea, vomiting, or fever occur, inform your doctor immediately. The metformin component can cause lactic acidosis, a rare but very serious metabolic complication, which can manifest as muscle pain, weakness, difficulty breathing, abdominal pain, or decreased consciousness. If these symptoms occur, stop taking the medication immediately and visit a hospital. This medication is not to be used in patients with impaired kidney function, severe heart failure, liver disease, pregnant or breastfeeding women, or those in certain acute disease states. A kidney function test must be performed before taking this medication, and regular checks of kidney function and blood tests should be conducted during treatment. Avoid excessive alcohol consumption while taking this medication, especially in cases of acute alcohol intoxication or poor nutritional status. Also, you should discontinue this medication for a certain period before and after surgery, so inform your healthcare provider if surgery is planned. This medication can cause low blood sugar, so caution is needed when skipping meals or when there is a sudden increase in physical activity. When combined with other antihyperglycemic agents, the risk of hypoglycemia may increase, so blood glucose levels should be monitored carefully. While taking this medication, side effects such as diarrhea, nausea, vomiting, headache, and upper respiratory tract infections may occur. If symptoms persist or worsen, consult a healthcare professional. Finally, this medication is not recommended for children under 18, pregnant women, or breastfeeding mothers. In elderly patients, careful monitoring is required due to the possible decline in kidney function.

Side effects

Anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent the ingress of air or moisture, ideally at room temperature between 1 to 30 degrees Celsius. Storing it this way will help to maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.